Summary Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m 2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity.
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There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
There is documented activity of vindesine (VDS) (Retsas et al., 1980) and dacarbazine (DTIC) (Comis, 1976; Constanzi, 1976; Pritchard et al., 1981) as single agents or in combination in malignant melanoma with objective response rates of 15-42% (Einhorn et al., 1974; Hill et al., 1984; Retsas et al., 1985) . Numerous attempts have been made to increase the response rate by combining various drugs. However, there is no evidence that any particular combination has improved these results (Einhorn et al., 1974; Karakousis et al., 1979) . Cisplatin (CDDP) alone or in combination with other active agents has been tried in patients with advanced malignant melanoma and has resulted in a wide range of remission rates (Chary et al., 1977; Nathanson et al., 1981; Al-Sarraf et al., 1982; York et al., 1983; Retsas et al., 1985; Wussow et al., 1987) .
Since DTIC, VDS and CDDP have different mode of action and toxicity, it was rational to combine these drugs in an effort to improve response rates and possibly response duration. Chemotherapy consisted of CDDP 120 mg m-2 as a 30 min infusion in 3% hypertonic saline with hydration and mannitol diuresis on day 1, VDS 3 mg m2 (no more than 5 mg) on day 2 as an i.v. bolus and DTIC 250 mg m2 on days 2-6 as an i.v. infusion over 30 min. The course was repeated every 4 weeks and doses were decreased according to the degree of haematological and renal toxicity of the preceding course.
Antiemetic treatment with metoclopramide 2 mg kg-' 0.5 h before and 1.5, 3.5, 5.5 and 8 h after CDDP administration plus dexamethasone 8 mg 3 h before and 3, 6 and 9 h after CDDP administration was given. On days 2-6 metoclopramide 2 mg kg-' plus dexamethasone 8 mg 0.5 h before and 3 h after DTIC administration were given.
Fourteen males and 13 females with a mean age of 54 years entered the trial. Patient characteristics are shown in Table I . The mean number of administered courses was four (range 1-8 courses). World Health Organization (WHO) response and toxicity criteria were used (WHO, 1979) .
Results
Response to therapy The response to therapy was as follows: complete response (CR) five (19%) patients, partial response (PR) seven (26%), stable (SD) or progressive disease (PD) 15 (55%). The median duration of CR was 4 + months (4,4,4,4.5,9 +) and of PR 8 months (3,4.5,5.5,8,10,11,18) . Tumour responses by site are shown in Table II . Metastases in the lungs, lymph nodes, subcutaneous tissues and skin were more responsive to chemotherapy. As shown in Table II 
Discussion
Although the prognosis of patients with disseminated malignant melanoma remains poor, intensive chemotherapy may produce remissions in a small number of patients. The antitumour effect of VDS in advanced malignant melanoma is at least comparable with, and probably superior to, DTIC (Retsas et al., 1980) . It has been reported that the response rate in disseminated malignant melanoma with CDDP alone or in combination with DTIC was no better than the rate obtained with DTIC alone (Friedman et al., 1979; Oratz et al., 1987) . The VBD (vinblastine, bleomycin, cisplatin) combination has been reported to give objective responses ranging from 0% (York et al., 1983) to 43% (Nathanson et al., 1981) .
Other investigators reported response rates in the intermediate range 10-41% (Creagan et al., 1981; Canadian Melanoma Group, 1984; Luikart et al., 1984; Mechl et al., 1985) . Carey et al. (1986) reported 25% CR + PR in previously untreated patients with metastatic malignant melanoma by using the VDD (vinblastine, dacarbazine, cisplatin) regime. The (B) DPV3 (Retsas et al., 1985) (cisplatin, vinblastine, vindesine ± bleomycin alternating with dacarbazine, vincristine) regime gave a 29% response rate despite more advanced disease at the onset of treatment. It was concluded that the addition of bleomycin to the DPV3 regime had no effect on response.
The response rate of 45% (CR + PR) for DVP combination in our study is slightly lower than that recently reported by Wussow et al. (1987) . Toxicity encountered in our patients was similar to those reported by Wussow et al. (1987) , who used an almost identical regime. The major difference between the previous studies and the present one is that they employed lower doses of cisplatin. Whether the increased dose is important or whether our and Wussow et al.'s (1987) better response rate was a chance occurrence cannot be determined. The sites most likely to respond to chemotherapy remain skin, lymph nodes and lungs and no responses were observed in hepatic and skeletal metastases.
The DVP combination as first line chemotherapy in disseminated malignant melanoma seems to yield a useful response rate with moderate toxicity, but the mean duration of response remains disappointing.
